More Articles

Positioning of biosimilars: commodity versus differentiated Reports | Posted 24/08/2012

How to market a new biosimilar is a key question, especially when taking into consideration the costs that are associated with developing a biosimilar. Whether the biosimilar will be a bulk (commod...

Facts about generics for patients Generics/Research | Posted 24/08/2012

The costs of health care are rising across Europe through ageing populations resulting in more patients with chronic diseases, stricter clinical targets for managing patients with long term (chroni...

New pharmaceutical law promotes generics in Chile Guidelines | Posted 24/08/2012

In July 2012, a new pharmaceutical law was introduced in Chile. The new law aims to regulate generics bioequivalence in the country as well as enforce prescription by generic name in order to incre...

Investigating G-CSF biosimilars approved in Europe Biosimilars/Research | Posted 24/08/2012

A life-threatening complication for patients undergoing chemotherapy is febrile neutropenia, involving a loss of neutrophils (white blood cells) and fever. Granulocyte colony-stimulating factors (G...

Attitude of general practitioners towards generics in Pakistan Generics/Research | Posted 24/08/2012

The second of a series of three articles reports on a survey aimed at exploring the knowledge, perception and attitude of general practitioners towards generic medicines in Karachi, Pakistan [1].

Sun Pharma finally gains full control of Taro Pharma News | Posted 24/08/2012

Sun Pharmaceutical Industries (Sun Pharma) and Taro Pharmaceutical Industries (Taro) announced on 13 August 2012 that they have entered into a merger agreement together. India-based Sun Pharma has...

FDA approval for generic diabetes drug Actos Generics/News | Posted 24/08/2012

On 17 August 2012, FDA gave final approval to Mylan Pharmaceuticals for the first generic version of Actos (pioglitazone hydrochloride tablets), for the treatment of type 2 diabetes. The approval c...

Fuji Pharma acquires OLIC Thailand Pharma News | Posted 24/08/2012

Fuji Pharma Co Ltd announced on 3 August 2012 that it has entered into an agreement to acquire the shares of OLIC (Thailand) Ltd, the largest pharmaceutical contract manufacturer in Thailand.